Hydroxyflutamide enhances cellular sensitivity to 5-fluorouracil by suppressing thymidylate synthase expression in bicalutamide-resistant human prostate cancer cells

International Journal of Oncology

Volumn 38, Issue 3, 2011, Pages 665-676

  Kawabata, Rumi ^a,b   Oie, Shinji ^b   Oka, Toshinori ^b   Takahashi, Masayuki ^a   Kanayama, Hiroomi ^a   Itoh, Kohji ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

5 fluorouracil; Anti androgen; E2F1; Prostate cancer; Thymidylate synthase

Indexed keywords

ANDROGEN RECEPTOR; BETA ACTIN; BICALUTAMIDE; FLUOROURACIL; HYDROXYFLUTAMIDE; THYMIDYLATE SYNTHASE; TRANSCRIPTION FACTOR E2F1;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CELL CULTURE; CELL PROLIFERATION; CELL STRAIN LNCAP; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; ENZYME REPRESSION; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

ANDROGEN ANTAGONISTS; ANILIDES; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA; CELL LINE, TUMOR; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FLUOROURACIL; FLUTAMIDE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MODELS, BIOLOGICAL; NEOPLASMS, HORMONE-DEPENDENT; NITRILES; PROSTATIC NEOPLASMS; THYMIDYLATE SYNTHASE; TOSYL COMPOUNDS;

EID: 79952014826     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.909     Document Type: Article

References (56)

1. Prostate Cancer Trialists' Collaborative Group: Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 355: 1491-1498, 2000.
2. Schmitt B, Wilt TJ, Schellhammer PF, et al: Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review. Urology 57: 727-732, 2001.
3. Oh WK and Kantoff PW: Management of hormone refractory prostate cancer: current standards and future prospects. J Urol 160: 1220-1229, 1998. (Pubitemid 29480485)
4. Kojima S, Suzuki H, Akakura K, Shimbo M, Ichikawa T and Ito H: Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. J Urol 171: 679-683, 2004. (Pubitemid 38090455)
5. Miyake H, Hara I and Eto H: Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer. BJU Int 96: 791-795, 2005. (Pubitemid 41391382)
6. Nishimura K, Arichi N, Tokugawa S, Yoshioka I, Kishikawa H and Ichikawa Y: Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer. Int J Urol 14: 264-267, 2007. (Pubitemid 46423250)
7. Gulley J, Figg WD and Dahut WL: Treatment options for androgen-independent prostate cancer. Clin Adv Hematol Oncol 1: 49-57, 2003.
8. Lara PN Jr and Meyers FJ: Treatment options in androgen-independent prostate cancer. Cancer Invest 17: 137-144, 1999.
9. Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512, 2004. (Pubitemid 39315317)
10. Petrylak DP, Tangen CM, Hussain MH, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513-1520, 2004. (Pubitemid 39315318)
11. Meyers M, Hwang A, Wagner MW, et al: A role for DNA mismatch repair in sensing and responding to fluoropyrimidine damage. Oncogene 22: 7376-7388, 2003.
12. Salonga D, Danenberg KD, Johnson M, et al: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6: 1322-1327, 2000. (Pubitemid 30226214)
13. Lurje G, Manegold PC, Ning Y, Pohl A, Zhang W and Lenz HJ: Thymidylate synthase gene variations: predictive and prognostic markers. Mol Cancer Ther 8: 1000-1007, 2009.
14. Ikeguchi M, Makino M and Kaibara N: Thymidine phosphorylase and dihydropyrimidine dehydrogenase activity in colorectal carcinoma and patients prognosis. Langenbecks Arch Surg 387: 240-245, 2002. (Pubitemid 36061870)
15. Carreras CW and Santi DV: The catalytic mechanism and structure of thymidylate synthase. Annu Rev Biochem 64: 721-762, 1995.
16. Costi MP, Ferrari S, Venturelli A, Calo S, Tondi D and Barlocco D: Thymidylate synthase structure, function and implication in drug discovery. Curr Med Chem 12: 2241-2258, 2005. (Pubitemid 41179710)
17. Johnston PG, Lenz HJ, Leichman CG, et al: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55: 1407-1412, 1995.
18. Miyoshi Y, Uemura H, Ishiguro H, et al: Expression of thymidylate synthase, dihydropyrimidine dehydrogenase, thymidine phosphorylase, and orotate phosphoribosyl transferase in prostate cancer. Prostate Cancer Prostatic Dis 8: 260-265, 2005. (Pubitemid 43118064)
19. Mizutani Y, Wada H, Yoshida O, et al: Significance of thymidylate synthase activity in renal cell carcinoma. Clin Cancer Res 9: 1453-1460, 2003. (Pubitemid 36418401)
20. Nomura T, Nakagawa M, Fujita Y, Hanada T, Mimata H and Nomura Y: Clinical significance of thymidylate synthase expression in bladder cancer. Int J Urol 9: 368-376, 2002. (Pubitemid 35001933)
21. Pestalozzi BC, Peterson HF, Gelber RD, et al: Prognostic importance of thymidylate synthase expression in early breast cancer. J Clin Oncol 15: 1923-1931, 1997.
22. Shintani Y, Ohta M, Hirabayashi H, et al: New prognostic indicator for non-small-cell lung cancer, quantitation of thymidylate synthase by real-time reverse transcription polymerase chain reaction. Int J Cancer 104: 790-795, 2003. (Pubitemid 36418519)
23. Suzuki M, Tsukagoshi S, Saga Y, Ohwada M and Sato I: Enhanced expression of thymidylate synthase may be of prognostic importance in advanced cervical cancer. Oncology 57: 50-54, 1999. (Pubitemid 29308671)
24. Li Y, Mizutani Y, Shiraishi T, et al: Prognostic significance of thymidylate synthase expression in patients with prostate cancer undergoing radical prostatectomy. Urology 69: 988-995, 2007. (Pubitemid 46670252)
25. Edler D, Hallstrom M, Johnston PG, Magnusson I, Ragnhammar P and Blomgren H: Thymidylate synthase expression: an independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer. Clin Cancer Res 6: 1378-1384, 2000. (Pubitemid 30226223)
26. Saotome K, Morita H and Umeda M: Cytotoxicity test with simplified crystal violet staining method using microtitre plates and its application to injection drugs. Toxicol In Vitro 3: 317-321, 1989. (Pubitemid 20019736)
27. Spears CP, Shahinian AH, Moran RG, Heidelberger C and Corbett TH: In vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas. Cancer Res 42: 450-456, 1982.
28. DeGregori J, Kowalik T and Nevins JR: Cellular targets for activation by the E2F1 transcription factor include DNA synthesis- and G1/S-regulatory genes. Mol Cell Biol 15: 4215-4224, 1995.
29. Dong S, Lester L and Johnson LF: Transcriptional control elements and complex initiation pattern of the TATA-less bidirectional human thymidylate synthase promoter. J Cell Biochem 77: 50-64, 2000. (Pubitemid 30126894)
30. Helin K: Regulation of cell proliferation by the E2F transcription factors. Curr Opin Genet Dev 8: 28-35, 1998.
31. Dyson N: The regulation of E2F by pRB-family proteins. Genes Dev 12: 2245-2262, 1998.
32. Gregory CW, Whang Ye, McCall W, et al: Heregulin-induced activation of HeR2 and HeR3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth. Clin Cancer Res 11: 1704-1712, 2005. (Pubitemid 40471831)
33. Chen T, Wang LH and Farrar WL: Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. Cancer Res 60: 2132-2135, 2000. (Pubitemid 30225173)
34. Lee SO, Lou W, Hou M, de Miguel F, Gerber L and Gao AC: Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clin Cancer Res 9: 370-376, 2003. (Pubitemid 36109754)
35. Malinowska K, Neuwirt H, Cavarretta IT, et al: Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor. Endocr Relat Cancer 16: 155-169, 2009.
36. Wen Y, Hu MC, Makino K, et al: HeR-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 60: 6841-6845, 2000. (Pubitemid 32059149)
37. Murillo H, Huang H, Schmidt LJ, Smith DI and Tindall DJ: Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology 142: 4795-4805, 2001. (Pubitemid 33022355)
38. Gao N, Zhang Z, Jiang BH and Shi X: Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem Biophys Res Commun 310: 1124-1132, 2003. (Pubitemid 37237653)
39. Pfeil K, Eder IE, Putz T, et al: Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells. Prostate 58: 259-268, 2004. (Pubitemid 38168923)
40. Sun M, Yang L, Feldman RI, et al: Activation of phosphatidylinositol 3-kinase/Akt pathway by androgen through interaction of p85alpha, androgen receptor, and Src. J Biol Chem 278: 42992-43000, 2003. (Pubitemid 37345912)
41. Liang J and Slingerland JM: Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2: 339-345, 2003.
42. Veldscholte J, Ris-Stalpers C, Kuiper GG, et al: A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 173: 534-540, 1990.
43. Steketee K, Timmerman L, Ziel-van der Made AC, Doesburg P, Brinkmann AO and Trapman J: Broadened ligand responsiveness of androgen receptor mutants obtained by random amino acid substitution of H874 and mutation hot spot T877 in prostate cancer. Int J Cancer 100: 309-317, 2002.
44. Trimarchi JM and Lees JA: Sibling rivalry in the E2F family. Nat Rev Mol Cell Biol 3: 11-20, 2002. (Pubitemid 135709914)
45. Dolnick BJ: Cloning and characterization of a naturally occurring antisense RNA to human thymidylate synthase mRNA. Nucleic Acids Res 21: 1747-1752, 1993.
46. Dolnick BJ, Black AR, Winkler PM, Schindler K and Hsueh CT: rTS gene expression is associated with altered cell sensitivity to thymidylate synthase inhibitors. Adv Enzyme Regul 36: 165-180, 1996. (Pubitemid 27065710)
47. Dolnick BJ, Angelino NJ, Dolnick R and Sufrin JR: A novel function for the rTS gene. Cancer Biol Ther 2: 364-369, 2003.
48. Kato H, Ichinose Y, Ohta M, et al: A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N engl J Med 350: 1713-1721, 2004. (Pubitemid 38501140)
49. Kasumi F, Yoshimoto M, Uchino J, et al: Meta-analysis of five studies on tegafur plus uracil (UFT) as post-operative adjuvant chemotherapy for breast cancer. Oncology 64: 146-153, 2003. (Pubitemid 36173380)
50. Taguchi T: Clinical application of biochemical modulation in cancer chemotherapy: biochemical modulation for 5-FU. Oncology 54 (Suppl. 1): S12-S18, 1997.
51. Tanaka F: UFT (tegafur and uracil) as postoperative adjuvant chemotherapy for solid tumors (carcinoma of the lung, stomach, colon/rectum, and breast): clinical evidence, mechanism of action, and future direction. Surg Today 37: 923-943, 2007.
52. Bhandari MS, Pienta KJ, Fardig J, Olson K and Smith DC: Phase II trial of oral uracil/tegafur plus leucovorin in patients with hormone-refractory prostate carcinoma. Cancer 106: 1715-1721, 2006.
53. Miyake H, Hara I, Yamazaki H and Eto H: Clinical outcome of oral uracil/tegafur (UFT) therapy for patients with hormone refractory prostate cancer. Oncol Rep 14: 673-676, 2005.
54. Kuriyama M, Takahashi Y, Sahashi M, et al: Prospective and randomized comparison of combined androgen blockade versus combination with oral UFT as an initial treatment for prostate cancer. Jpn J Clin Oncol 31: 18-24, 2001. (Pubitemid 32236882)
55. Sakai H, Minami Y, Kanetake H and Saito Y: Chemo-endocrine therapy for prostate cancer with bone metastasis. Nagasaki Prostate Cancer Research Group. Cancer Chemother Pharmacol 35 (Suppl.): S23-S26, 1994.
56. Sumiyoshi Y, Hashine K, Kuwahara M, et al: [Primary treatment for stage D2 prostate cancer: a randomized study of combined androgen blockade alone versus combined with UFT]. Gan To Kagaku Ryoho 26: 1153-1158, 1999.